Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.
Y, I., R, K., Y, T., H, M., K, M., M, N., W, S., T, N., N, T., & R, K. (2026). Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.. Sensors (Basel, Switzerland). https://doi.org/10.3390/s26123952
Y I, R K, Y T, H M, K M, M N, et al. Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.. Sensors (Basel, Switzerland). 2026; doi: 10.3390/s26123952
Y I, R K, Y T, et al. Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.[J]. Sensors (Basel, Switzerland). 2026. DOI: 10.3390/s26123952.
@article{y2026,
author = {Ikeda Y and Kanai R and Terazaki Y and Mori H and Matsumoto K and Narita M and Sasaki W and Naganuma T and Tanaka N and Kato R},
title = {Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator.},
journal = {Sensors (Basel, Switzerland)},
year = {2026},
doi = {10.3390/s26123952},
note = {PMID: 42356925},
}
TY - JOUR AU - Ikeda Y AU - Kanai R AU - Terazaki Y AU - Mori H AU - Matsumoto K AU - Narita M AU - Sasaki W AU - Naganuma T AU - Tanaka N AU - Kato R TI - Clinical Utility of the TRENDS Remote Monitoring Function Integrated into a Wearable Cardioverter-Defibrillator. T2 - Sensors (Basel, Switzerland) PY - 2026 DO - 10.3390/s26123952 AN - PMID:42356925 ER -
BACKGROUND: Wearable cardioverter-defibrillators (WCDs) are equipped with the TRENDS remote-monitoring system, enabling continuous assessment of arrhythmias, physiological parameters, and patient-reported outcomes. This study evaluated the clinical utility of TRENDS-integrated WCD management and compared it with a historical control. METHODS: We prospectively analyzed 36 consecutive patients who received a WCD with TRENDS between 2019 and 2024 and compared them with 30 historical controls treated before the implementation of TRENDS. RESULTS: The WCD indications were heart failure as primary prevention (64%) and acute coronary syndrome with ventricular arrhythmias (28%). Among 18 patients who met the criteria for an implantable cardioverter-defibrillator (ICD), including 1 patient with WCD shock, 9 ultimately underwent ICD implantation. The mean daily WCD wear-time was 21.3 h and did not differ significantly from that of the historical control. The response rate to health-related questionnaires was 89%. TRENDS detected symptom exacerbation in 31% of patients, weight gain in 19% of patients, and missed medication in 19% of patients. Daily step-count was significantly lower in patients with ICD indications than in those without (5012 ± 2980 steps vs. 7977 ± 3584 steps, p = 0.01). TRENDS data also aided in initiating anticoagulation therapy and optimizing beta-blocker therapy. CONCLUSIONS: TRENDS provided clinically actionable physiologic and patient-reported information that supported individualized cardiovascular management.